drugset / Trial / NCT05318963
Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma
Phase 1
Terminated
14 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LCAR-AIO, a triple-targeted cell preparation targeting CD19/CD20/CD22, in patients with relapsed/refractory B-cell lymphoma.
Timeline
- Start
- 2022-03-14
- Primary completion
- 2025-01-17
- Completion
- 2025-03-31
Outcome
Outcome not reported
Stopped: “The collaborators decided to terminate this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-AIO | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Fludarine | Unknown | 30 mg/m2 | — |